Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Hormone replacement in menopausal women with multiple sclerosis: Looking back, thinking forward.
Progressive solitary sclerosis: Gradual motor impairment from a single CNS demyelinating lesion.
Role of Sonic Hedgehog Signaling in Oligodendrocyte Differentiation.
[Fingolimod: effectiveness and safety in routine clinical practice. An observational, retrospective, multi-centre study in Galicia].
THE EFFECT OF EDUCATIONAL INTERVENTION ON KNOWLEDGE AND SELF-EFFICACY FOR PAIN CONTROL IN PATIENTS WITH MULTIPLE SCLEROSIS.
The Impact of MS-Related Cognitive Fatigue on Future Brain Parenchymal Loss and Relapse: A 17-Month Follow-up Study.
Treatment with NAD(+) inhibited experimental autoimmune encephalomyelitis by activating AMPK/SIRT1 signaling pathway and modulating Th1/Th17 immune responses in mice.
Adipose-Derived Cells (Stromal Vascular Fraction) Transplanted for Orthopedical or Neurological Purposes: Are They Safe Enough?
Inadequate outcome measures are the biggest impediment to successful clinical trials in progressive MS - Commentary.
Severe inflammatory disease activity 14 months after cessation of Natalizumab in a patient with Leber's optic neuropathy and multiple sclerosis - a case report.
Long-term effects of autoimmune CNS inflammation on adult hippocampal neurogenesis.
Genetic Leukoencephalopathies in Adults.
Exercise Training and Cognitive Rehabilitation: A Symbiotic Approach for Rehabilitating Walking and Cognitive Functions in Multiple Sclerosis?
Multiple sclerosis: The resolving lesion revealed.
Dimethyl fumarate restores apoptosis sensitivity and inhibits tumor growth and metastasis in CTCL by targeting NFκB.
Assessment of vitamin D status - a changing landscape.
The Incidence of Euphoria in Multiple Sclerosis: Artefact of Measure.
Epigenetic Modifications and Therapy in Multiple Sclerosis.
Distribution-based estimates of minimum clinically important difference in cognition, arm function and lower body function after slow release-fampridine treatment of patients with multiple sclerosis.
How long is the presymptomatic phase of multiple sclerosis?
Grey matter atrophy is associated with disability increase in natalizumab-treated patients.
Mutations in MYT1, encoding the myelin transcription factor 1, are a rare cause of OAVS.
Growing Older With a Physical Disability: A Special Application of the Successful Aging Paradigm.
Rituximab for treating multiple sclerosis: Off-label but on target.
The role of anti-aquaporin 4 antibody in the conversion of acute brainstem syndrome to neuromyelitis optica.

Pages